The DOI matches its Crossref record; 55 of the 55 references it cites were found in a registry or an index.
Gene Transfer of Human Apoe Isoforms Results in Differential Modulation of Amyloid Deposition and Neurotoxicity in Mouse Brain
Open accessAbstract
Introduction of different APOE isoforms modulates Aβ peptide aggregation and neurotoxicity after amyloid deposition in mouse brain.
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“Based on these observations, one strategy to prevent AD in APOE4 carriers is to modify the central nervous system (CNS) genetically to express APOE2, providing the CNS with the protective APOE2 to balance the AD risk associated with expression of APOE4.22–26”
From AAVrh.10-Mediated APOE2 Central Nervous System Gene Therapy for APOE4-Associated Alzheimer's Disease (2018) · cites this paper as [24]
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“Previous studies using homozygous APOE knock-in mice have been essential for de fi ning isoform-speci fi c effects of APOE2 , APOE3 , and APOE4”
From APOE2 attenuates APOE4-associated amyloid pathology and related toxicity in a mouse model of Alzheimer’s disease (2026) · cites this paper as [33]
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“Moving in vivo, other studies have explored vector-mediated delivery to supplement the E4 brain with neuroprotective E2 protein, showing that exogenous E2 markedly decreases amyloid burden in mice9–12.”
From APOE4 to APOE2 allelic switching in mice improves Alzheimer’s disease-related metabolic signatures, neuropathology and cognition (2025) · cites this paper as [10]
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“Expression of apoE3 and apoE4 in the mouse brain results in diminished efflux of A into the blood compared with apoE2 (Hudry et al., 2013).”
From Anti-ApoE Antibody Given after Plaque Onset Decreases Aβ Accumulation and Improves Brain Function in a Mouse Model of Aβ Amyloidosis (2014) · cites this paper as Hudry et al., 2013
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“overexpression of human APOE ε2 allele in APP/PS1 mice was able to attenuate brain Aβ oligomerization and plaque deposition, as well as peri-plaque synapse loss and neurite dystrophy, in contrast to the injection of ApoE4-encoding AAVs [79].”
From Apoe4 and Alzheimer’s Disease Pathogenesis—Mitochondrial Deregulation and Targeted Therapeutic Strategies (2023) · cites this paper as [79]
Experimental — accuracy not yet measured
The source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“M-apoE and h-apoE differ in both structure [119] and functions ranging from lipid binding and transport, to effects on AD pathology [22, 84, 85, 119, 120].”
From Inhibition of ACAT as a Therapeutic Target for Alzheimer's Disease Is Independent of ApoE4 Lipidation (2023) · cites this paper as [120]
Experimental — accuracy not yet measuredThe cited source says what the claim attributes to it.
In the citing paper
“The protective effect of APOE2 genetic modification of the CNS was replicated by Hudry et al.24 using an adeno-associated virus serotype 4 (AAV4) vector to deliver APOE2 into the cerebrospinal fluid (CSF) of the lateral ventricle of mice overexpressing a mutant β-amyloid precursor protein (APP) transgene”
From AAVrh.10-Mediated APOE2 Central Nervous System Gene Therapy for APOE4-Associated Alzheimer's Disease (2018) · cites this paper as [24]
The cited source says what the claim attributes to it.
In the citing paper
“The efficacy of this approach in AD transgenic mouse models has been demonstrated previously.23,24,26”
From AAVrh.10-Mediated APOE2 Central Nervous System Gene Therapy for APOE4-Associated Alzheimer's Disease (2018) · cites this paper as [24]
The cited source says what the claim attributes to it.
In the citing paper
“while viral APOE2 delivery, APOE2 gene therapy, and inducible APOE4 to APOE2 switching have demonstrated that increasing APOE2 expression or replacing APOE4 with APOE2 can ameliorate AD-related phenotypes 7,8,33,34 .”
From APOE2 attenuates APOE4-associated amyloid pathology and related toxicity in a mouse model of Alzheimer’s disease (2026) · cites this paper as [33]
The cited source says what the claim attributes to it.
In the citing paper
“APOE exerts toxic effects on the cerebrovascular system (694) and neurons (383, 384) and influences A 𝛃 clearance (60, 64, 98, 135, 256, 266, 278, 294, 315, 693), amyloid deposition (39, 256, 258, 266, 278, 314, 518, 612), and tau-related neurodegeneration (533) in an allele-dependent manner APOE4 > APOE3 > APOE2 .”
From Blood-Brain Barrier: From Physiology to Disease and Back (2019) · cites this paper as [266]
The cited source says what the claim attributes to it.
In the citing paper
“Epidemiological evidence and evidence from neuropathological assessment of the impact of apoE isoforms on the brain Aβ load, have suggested that apoE2 exerts a protective effect against Aβ pathology and AD morbidity [3,9,10], while apoE4, in contrast, markedly enhances the disease process [7,8,30].”
From Blocking the apoE/Aβ interaction ameliorates Aβ-related pathology in APOE ε2 and ε4 targeted replacement Alzheimer model mice (2014) · cites this paper as [30]
The cited source says what the claim attributes to it.
In the citing paper
“ApoE plays an important role in amyloidosis progression (Dodart et al., 2005;Hudry et al., 2013).”
From Anti-ApoE Antibody Given after Plaque Onset Decreases Aβ Accumulation and Improves Brain Function in a Mouse Model of Aβ Amyloidosis (2014) · cites this paper as Hudry et al., 2013
The cited source says what the claim attributes to it.
In the citing paper
“Unlike other two isoforms, apoE2 has not been studies extensively but consistent data appear to support its neuroprotective function (Hudry et al., 2013).”
From Apolipoprotein E in Synaptic Plasticity and Alzheimer’s Disease: Potential Cellular and Molecular Mechanisms (2014) · cites this paper as Hudry et al., 2013
The cited source says what the claim attributes to it.
In the citing paper
“These results bear a striking resemblance to those from the Aβ plaque-depositing mice120,128 and indicate that the effect of APOE4 in AD is due not only to the increased propensity of proteins to aggregate in the presence of APOE4, but also to the way APOE4 modulates the brain response to those aggregates once formed.”
From Multifaceted roles of APOE in Alzheimer disease (2024) · cites this paper as [128]
The cited source says what the claim attributes to it.
In the citing paper
“The introduction of human APOE2 into plaque-depositing mice expressing endogenous mouse Apoe via AAV-mediated delivery was shown to prevent and even reverse the deposition of Aβ into plaques, whereas delivery of APOE4 had the opposite effect128”
From Multifaceted roles of APOE in Alzheimer disease (2024) · cites this paper as [128]
The cited source says what the claim attributes to it.
In the citing paper
“In general, experiments suggest the order of APOE4 > APOE3 > APOE2 for effects on amyloid deposition (Fagan et al, 2002; Castellano et al, 2011; Hudry et al, 2013; Zhao et al, 2016)”
From APOE from astrocytes restores Alzheimer’s Aβ-pathology and DAM-like responses in APOE deficient microglia (2024) · cites this paper as Hudry et al, 2013
The cited source says what the claim attributes to it.
In the citing paper
“This has also been observed with viral-vector mediated overexpression of APOE4 isoforms in AD mouse brains (Dodart et al, 2005; Hudry et al, 2013; Zhao et al, 2016).”
From APOE from astrocytes restores Alzheimer’s Aβ-pathology and DAM-like responses in APOE deficient microglia (2024) · cites this paper as Hudry et al, 2013
The check wasn’t confident either way, so it gives no verdict — never disputed.
In the citing paper
“using a previously published split-luciferase complementation assay34”
From Resistance to autosomal dominant Alzheimer’s disease in an APOE3 Christchurch homozygote: a case report (2019) · cites this paper as [34]
Experimental — accuracy not yet measuredIn the citing paper
“While there is data to support the concept that ApoE2 expression may be protective using a gene transfer approach (Hu et al., 2015; Hudry et al., 2013), it would be useful to validate protective effects and lack of toxicity in a number of different models.”
From Alzheimer Disease: An Update on Pathobiology and Treatment Strategies (2019) · cites this paper as Hudry et al., 2013
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Corder, E. H., Saunders, A. M., Strittmatter, W. J., Schmechel, D. E., Gaskell, P. C., Small, G. W., Roses, A. D., Haines, J. L., & Pericak-Vance, M. A. (1993) · Science · doi:10.1126/science.8346443 · Cited by 9,429
Alzheimer's Disease: Genes, Proteins, and Therapy
Selkoe, D. J. (2001) · Physiological Reviews · doi:10.1152/physrev.2001.81.2.741 · Cited by 6,063
Terry, R. D., Masliah, E., Salmon, D. P., Butters, N., DeTeresa, R., Hill, R., Hansen, L. A., & Katzman, R. (1991) · Annals of Neurology · doi:10.1002/ana.410300410 · Cited by 4,397
Correlative Memory Deficits, Aβ Elevation, and Amyloid Plaques in Transgenic Mice
Hsiao, K., Chapman, P., Nilsen, S., Eckman, C., Harigaya, Y., Younkin, S., Yang, F., & Cole, G. (1996) · Science · doi:10.1126/science.274.5284.99 · Cited by 4,210
The molecular pathology of Alzheimer's disease
Selkoe, D. J. (1991) · Neuron · doi:10.1016/0896-6273(91)90052-2 · Cited by 2,708
Shankar, G. M., Bloodgood, B. L., Townsend, M., Walsh, D. M., Selkoe, D. J., & Sabatini, B. L. (2007) · The Journal of Neuroscience · doi:10.1523/jneurosci.4970-06.2007 · Cited by 1,592
Apolipoprotein E controls cerebrovascular integrity via cyclophilin A
Bell, R. D., Winkler, E. A., Singh, I., Sagare, A. P., Deane, R., Wu, Z., Holtzman, D. M., Betsholtz, C., Armulik, A., Sallstrom, J., et al. (2012) · Nature · doi:10.1038/nature11087 · Cited by 1,293
Human ApoE isoforms differentially regulate brain amyloid-β peptide clearance
Castellano, J. M., Kim, J., Stewart, F. R., Jiang, H., DeMattos, R. B., Patterson, B. W., Fagan, A. M., Morris, J. C., Mawuenyega, K. G., Cruchaga, C., et al. (2011) · Science Translational Medicine · doi:10.1126/scitranslmed.3002156 · Cited by 1,242
Apolipoprotein E in sporadic Alzheimer's disease: Allelic variation and receptor interactions
William Rebeck, G., Reiter, J. S., Strickland, D. K., & Hyman, B. T. (1993) · Neuron · doi:10.1016/0896-6273(93)90070-8 · Cited by 1,107
Self-citationApoE-Directed Therapeutics Rapidly Clear β-Amyloid and Reverse Deficits in AD Mouse Models
Cramer, P. E., Cirrito, J. R., Wesson, D. W., Lee, C. Y. D., Karlo, J. C., Zinn, A. E., Casali, B. T., Restivo, J. L., Goebel, W. D., James, M. J., et al. (2012) · Science · doi:10.1126/science.1217697 · Cited by 1,050
Borchelt, D. R., Ratovitski, T., van Lare, J., Lee, M. K., Gonzales, V., Jenkins, N. A., Copeland, N. G., Price, D. L., & Sisodia, S. S. (1997) · Neuron · doi:10.1016/s0896-6273(00)80974-5 · Cited by 1,023
Holtzman, D. M., Bales, K. R., Tenkova, T., Fagan, A. M., Parsadanian, M., Sartorius, L. J., Mackey, B., Olney, J., McKeel, D., Wozniak, D., et al. (2000) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.050004797 · Cited by 937
ApoE Promotes the Proteolytic Degradation of Aβ
Jiang, Q., Lee, C. Y. D., Mandrekar, S., Wilkinson, B., Cramer, P., Zelcer, N., Mann, K., Lamb, B., Willson, T. M., Collins, J. L., et al. (2008) · Neuron · doi:10.1016/j.neuron.2008.04.010 · Cited by 876
Koffie, R. M., Meyer-Luehmann, M., Hashimoto, T., Adams, K. W., Mielke, M. L., Garcia-Alloza, M., Micheva, K. D., Smith, S. J., Kim, M. L., Lee, V. M., et al. (2009) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0811698106 · Cited by 850
Self-citationApolipoprotein E: a pathological chaperone protein in patients with cerebral and systemic amyloid
Wisniewski, T., & Frangione, B. (1992) · Neuroscience Letters · doi:10.1016/0304-3940(92)90444-c · Cited by 802
Micheva, K. D., & Smith, S. J. (2007) · Neuron · doi:10.1016/j.neuron.2007.06.014 · Cited by 787
apoE isoform–specific disruption of amyloid β peptide clearance from mouse brain
Deane, R., Sagare, A., Hamm, K., Parisi, M., Lane, S., Finn, M. B., Holtzman, D. M., & Zlokovic, B. V. (2008) · Journal of Clinical Investigation · doi:10.1172/jci36663 · Cited by 771
Apolipoprotein E and Alzheimer disease.
Strittmatter, W. J., & Roses, A. D. (1995) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.92.11.4725 · Cited by 701
Astrocytes synthesize apolipoprotein E and metabolize apolipoprotein E-containing lipoproteins
Pitas, R. E., Boyles, J. K., Lee, S. H., Foss, D., & Mahley, R. W. (1987) · Biochimica et Biophysica Acta (BBA) - Lipids and Lipid Metabolism · doi:10.1016/0005-2760(87)90295-5 · Cited by 693
Spires, T. L., Meyer-Luehmann, M., Stern, E. A., McLean, P. J., Skoch, J., Nguyen, P. T., Bacskai, B. J., & Hyman, B. T. (2005) · The Journal of Neuroscience · doi:10.1523/jneurosci.1879-05.2005 · Cited by 550 · cited 3×
“ScienceTr alteration of the neuropil with an increased neurite curvature and the appearance of swollen dystrophies (30).”
BackgroundMethodSelf-citationApolipoprotein E ϵ4 and cerebral hemorrhage associated with amyloid angiopathy
Greenberg, S. M., Rebeck, G. W., Vonsattel, J. P., Gómez‐Isla, T., & Hyman, B. T. (1995) · Annals of Neurology · doi:10.1002/ana.410380219 · Cited by 547
Self-citationApolipoprotein E and Alzheimer's disease
Strittmatter, W. J., & Roses, A. D. (1996) · Annual Review of Neuroscience · doi:10.1146/annurev.ne.19.030196.000413 · Cited by 477
Structural Correlates of Cognition in Dementia: Quantification and Assessment of Synapse Change
DeKosky, S. T., Scheff, S. W., & Styren, S. D. (1996) · Neurodegeneration · doi:10.1006/neur.1996.0056 · Cited by 405
Cirrito, J. R., May, P. C., O'Dell, M. A., Taylor, J. W., Parsadanian, M., Cramer, J. W., Audia, J. E., Nissen, J. S., Bales, K. R., Paul, S. M., et al. (2003) · The Journal of Neuroscience · doi:10.1523/jneurosci.23-26-08844.2003 · Cited by 394
Wu, H.-Y., Hudry, E., Hashimoto, T., Kuchibhotla, K., Rozkalne, A., Fan, Z., Spires-Jones, T., Xie, H., Arbel-Ornath, M., Grosskreutz, C. L., et al. (2010) · The Journal of Neuroscience · doi:10.1523/jneurosci.4456-09.2010 · Cited by 367
Self-citationApolipoprotein E4 effects in Alzheimer’s disease are mediated by synaptotoxic oligomeric amyloid-β
Koffie, R. M., Hashimoto, T., Tai, H.-C., Kay, K. R., Serrano-Pozo, A., Joyner, D., Hou, S., Kopeikina, K. J., Frosch, M. P., Lee, V. M., et al. (2012) · Brain · doi:10.1093/brain/aws127 · Cited by 327
Self-citationApolipoprotein E, Especially Apolipoprotein E4, Increases the Oligomerization of Amyloid β Peptide
Hashimoto, T., Serrano-Pozo, A., Hori, Y., Adams, K. W., Takeda, S., Banerji, A. O., Mitani, A., Joyner, D., Thyssen, D. H., Bacskai, B. J., et al. (2012) · The Journal of Neuroscience · doi:10.1523/jneurosci.1542-12.2012 · Cited by 294 · cited 2×
“These results also are consistent with our recent observation that oligomeric Ab is elevated in the CNS of human patients with AD with APOE4 > APOE3 (even when plaque burden is normalized across cases) (26).”
BackgroundResultSelf-citationFagan, A. M., Watson, M., Parsadanian, M., Bales, K. R., Paul, S. M., & Holtzman, D. M. (2002) · Neurobiology of Disease · doi:10.1006/nbdi.2002.0483 · Cited by 290
Kim, J., Castellano, J. M., Jiang, H., Basak, J. M., Parsadanian, M., Pham, V., Mason, S. M., Paul, S. M., & Holtzman, D. M. (2009) · Neuron · doi:10.1016/j.neuron.2009.11.013 · Cited by 274
APOE4-specific Changes in Aβ Accumulation in a New Transgenic Mouse Model of Alzheimer Disease
Youmans, K. L., Tai, L. M., Nwabuisi-Heath, E., Jungbauer, L., Kanekiyo, T., Gan, M., Kim, J., Eimer, W. A., Estus, S., Rebeck, G. W., et al. (2012) · Journal of Biological Chemistry · doi:10.1074/jbc.m112.407957 · Cited by 268 · cited 1×
“Indeed, previous studies have shown that less APOE4 is lipoprotein-associated compared with APOE2 and APOE3 so that increasing the levels of delipidated versus lipidated lipoproteins may be one mechanism for the differential effects of APOE isoforms on Ab accumulation and retention in the brain (36, 37).”
BackgroundLee, E. B., Leng, L. Z., Zhang, B., Kwong, L. K., Trojanowski, J. Q., Abel, T. G., & Lee, V. M. ‐. (2005) · Journal of Biological Chemistry · doi:10.1074/jbc.m511018200 · Cited by 254
ApoE4 Decreases Spine Density and Dendritic Complexity in Cortical Neurons In Vivo
Dumanis, S. B., Tesoriero, J. A., Babus, L. W., Nguyen, M. T., Trotter, J. H., Ladu, M. J., Weeber, E. J., Turner, R. S., Xu, B., Rebeck, G. W., et al. (2009) · The Journal of Neuroscience · doi:10.1523/jneurosci.4026-09.2009 · Cited by 220
Xia, W., Yang, T., Shankar, G. M., Smith, I. M., Shen, Y., Walsh, D. M., & Selkoe, D. J. (2009) · Archives of Neurology · doi:10.1001/archneurol.2008.565 · Cited by 218
Hudry, E., Dam, D. V., Kulik, W., Deyn, P. P. D., Stet, F. S., Ahouansou, O., Benraiss, A., Delacourte, A., Bougneres, P. F., Aubourg, P. R., et al. (2009) · Molecular Therapy · doi:10.1038/mt.2009.175 · Cited by 214
Self-citationDodart, J.-C., Marr, R. A., Koistinaho, M., Gregersen, B. M., Malkani, S., Verma, I. M., & Paul, S. M. (2005) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0409072102 · Cited by 207
Kim, J., Jiang, H., Park, S., Eltorai, A. E. M., Stewart, F. R., Yoon, H., Basak, J. M., Finn, M. B., & Holtzman, D. M. (2011) · The Journal of Neuroscience · doi:10.1523/jneurosci.3773-11.2011 · Cited by 204
Frequency of the apolipoprotein E ε2 allele is diminished in sporadic Alzheimer disease
West, H. L., William Rebeck, G., & Hyman, B. T. (1994) · Neuroscience Letters · doi:10.1016/0304-3940(94)91074-x · Cited by 125
Self-citationLiu, G., Martins, I., Wemmie, J. A., Chiorini, J. A., & Davidson, B. L. (2005) · Journal of Neuroscience · doi:10.1523/jneurosci.2936-05.2005 · Cited by 120
Self-citationAn inherited variable poly-T repeat genotype in TOMM40 in Alzheimer disease
Roses, A. D. (2010) · Archives of Neurology · doi:10.1001/archneurol.2010.88 · Cited by 118
Aggregation and disaggregation of senile plaques in Alzheimer disease
Cruz, L., Urbanc, B., Buldyrev, S. V., Christie, R. H., Gómez‐Isla, T., Havlin, S., McNamara, M. J., Stanley, E., & Hyman, B. T. (1997) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.94.14.7612 · Cited by 115
Self-citationBrodbeck, J., McGuire, J., Liu, Z., Meyer-Franke, A., Balestra, M. E., Jeong, D.-E., Pleiss, M., McComas, C., Hess, F., Witter, D., et al. (2011) · Journal of Biological Chemistry · doi:10.1074/jbc.m110.217380 · Cited by 113
Imaging Amyloid-β Deposits In Vivo
Bacskai, B. J., Klunk, W. E., Mathis, C. A., & Hyman, B. T. (2002) · Journal of Cerebral Blood Flow & Metabolism · doi:10.1097/00004647-200209000-00001 · Cited by 106
Self-citationIrizarry, M. C., Cheung, B. S., Rebeck, G. W., Paul, S. M., Bales, K. R., & Hyman, B. T. (2000) · Acta Neuropathologica · doi:10.1007/s004010000263 · Cited by 93
Self-citationKuszczyk, M. A., Sanchez, S., Pankiewicz, J., Kim, J., Duszczyk, M., Guridi, M., Asuni, A. A., Sullivan, P. M., Holtzman, D. M., & Sadowski, M. J. (2013) · The American Journal of Pathology · doi:10.1016/j.ajpath.2013.01.034 · Cited by 89
Liu, G., Martins, I. H., Chiorini, J. A., & Davidson, B. L. (2005) · Gene Therapy · doi:10.1038/sj.gt.3302554 · Cited by 84
Self-citationSen, A., Alkon, D. L., & Nelson, T. J. (2012) · Journal of Biological Chemistry · doi:10.1074/jbc.m111.312710 · Cited by 73
Bekris, L. M., Galloway, N. M., Montine, T. J., Schellenberg, G. D., & Yu, C. (2009) · American Journal of Medical Genetics Part B Neuropsychiatric Genetics · doi:10.1002/ajmg.b.30993 · Cited by 63
Novel microdialysis method to assess neuropeptides and large molecules in free-moving mouse
Takeda, S., Sato, N., Ikimura, K., Nishino, H., Rakugi, H., & Morishita, R. (2011) · Neuroscience · doi:10.1016/j.neuroscience.2011.04.035 · Cited by 62
Self-citationPage, K. J., Hollister, R. D., & Hyman, B. T. (1998) · Neuroscience · doi:10.1016/s0306-4522(97)00661-1 · Cited by 57
Self-citationDeMattos, R. B. (2004) · Journal of Molecular Neuroscience · doi:10.1385/jmn:23:3:255 · Cited by 55
Traumatic brain injury induces biphasic upregulation of ApoE and ApoJ protein in rats
Iwata, A., Browne, K. D., Chen, X., Yuguchi, T., & Smith, D. H. (2005) · Journal of Neuroscience Research · doi:10.1002/jnr.20607 · Cited by 53
Bachmeier, C., Beaulieu-Abdelahad, D., Crawford, F., Mullan, M., & Paris, D. (2013) · Journal of Molecular Neuroscience · doi:10.1007/s12031-012-9866-6 · Cited by 39
Potential Role of apoE in Structural Plasticity in the Nervous System
Holtzman, D. M., & Fagan, A. M. (1998) · Trends in Cardiovascular Medicine · doi:10.1016/s1050-1738(98)00017-6 · Cited by 30
Srivastava, N., Averna, M. R., & Srivastava, R. A. K. (2008) · Annals of Neurosciences · doi:10.5214/ans.0972.7531.2008.150401 · Cited by 7
Srivastava, N., Averna, M. R., & Srivastava, R. A. K. (2008) · Nova Science Publishers (Nova Science Publishers, Inc.) · doi:10.5214/93 · Cited by 2
Cited by
Sorted by citations
Alzheimer Disease: An Update on Pathobiology and Treatment Strategies
Long, J. M., & Holtzman, D. M. (2019) · Cell · doi:10.1016/j.cell.2019.09.001 · Cited by 3,204
Blood-Brain Barrier: From Physiology to Disease and Back
Sweeney, M. D., Zhao, Z., Montagne, A., Nelson, A. R., & Zlokovic, B. V. (2019) · Physiological Reviews · doi:10.1152/physrev.00050.2017 · Cited by 2,312
Amyloid Beta: Structure, Biology and Structure-Based Therapeutic Development
Chen, G.-F., Xu, T.-H., Yan, Y., Zhou, Y.-R., Jiang, Y., Melcher, K., & Xu, H. E. (2017) · Acta Pharmacologica Sinica · doi:10.1038/aps.2017.28 · Cited by 1,965
Apolipoprotein E and Alzheimer disease: pathobiology and targeting strategies
Yamazaki, Y., Zhao, N., Caulfield, T. R., Liu, C.-C., & Bu, G. (2019) · Nature Reviews Neurology · doi:10.1038/s41582-019-0228-7 · Cited by 1,425
APOE and Alzheimer’s disease: Advances in genetics, pathophysiology, and therapeutic approaches
Serrano-Pozo, A., Das, S., & Hyman, B. T. (2021) · The Lancet Neurology · doi:10.1016/s1474-4422(20)30412-9 · Cited by 1,037
Self-citation
Metadata
- Authors
- Hudry, E., Dashkoff, J., Roe, A. D., Takeda, S., Koffie, R. M., Hashimoto, T., Scheel, M., Spires-Jones, T., Arbel-Ornath, M., Betensky, R., Davidson, B. L., & Hyman, B. T.
- Affiliations
- MassGeneral Institute for Neurodegenerative Disease, Massachusetts General Hospital and Harvard Medical School, Charlestown, MA 02129, USA.
- Harvard University (US)
- University of Iowa (US)
- Corresponding author
- Hyman, Bradley T.
- ORCID
- Venue
- Science Translational Medicine
- Published
- 2013-11-20
- Volume
- 5
- Issue
- 212
- Pages
- 212ra161-212ra161
- ISSN
- 1946-6234 (ISSN-L)
- 1946-6242
- PMC
- PMC4334150
- OpenAlex
- W2136199683
- Cited by
- 187
- References
- 55
- Citations by year
- 2026: 8 · 2025: 24 · 2024: 21 · 2023: 12 · 2022: 13 · 2021: 14 · 2020: 15 · 2019: 14 · 2018: 15 · 2017: 5 · 2016: 19 · 2015: 9 · 2014: 18
- FWCI
- 10.68
- Type
- journal article
- Language
- en
- Open access
- green
- www.ncbi.nlm.nih.gov
- Locations
- Science Translational Medicine (publishedVersion)
- PubMed (publishedVersion)
- PubMed Central (acceptedVersion)
- Funders
- Japan Society for the Promotion of Science (24800015)
- National Institute on Aging (R00AG033670, P50AG005134, 1RC1AG026265-01, R00AG33670, P30AG062421)
- National Institute on Drug Abuse (F32DA026265)
- National Institute of Diabetes and Digestive and Kidney Diseases (DK54759, P30DK054759)
- National Institute of Neurological Disorders and Stroke (NS 34568, R01NS034568)
- National Institute of Environmental Health Sciences (P30ES005605)
- Eunice Kennedy Shriver National Institute of Child Health and Human Development (HD-33531, R01HD033531)
- Topics
- Life Sciences › Neuroscience › Cellular and Molecular Neuroscience › Alzheimer's disease research and treatments
- Life Sciences › Neuroscience › Neurology › Neuroinflammation and Neurodegeneration Mechanisms
- Health Sciences › Medicine › Psychiatry and Mental health › Dementia and Cognitive Impairment Research
- Keywords
- apolipoprotein E, APOE isoforms, APOE ε4, APOE2, Alzheimer's disease, amyloid-beta, synaptotoxicity, amyloid-beta oligomers, amyloid-beta clearance, dystrophic neurites, synaptic loss, gene transfer, transgenic mouse model, genetic risk
- MeSH terms
- Amyloid, Animals, Apolipoproteins E, Brain, Humans, Injections, Intraventricular, Mice, Transgenic, Transfection, Mice
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
